INAB · In8bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.61M | - | $2.10M | $2.49M | $2.97M | - | $3.31M | $5.16M | $4.90M | - |
| SG&A | $2.65M | - | $1.86M | $2.71M | $2.69M | - | $2.73M | $3.53M | $3.74M | - |
| Total Operating Expenses | $5.27M | - | $3.97M | $5.20M | $5.66M | - | $7.11M | $8.69M | $8.64M | - |
| D&A | $245.0K | - | $200.0K | $300.0K | $256.0K | - | $300.0K | $200.0K | $239.0K | - |
| Operating Income | ($5.09M) | - | ($3.85M) | ($5.09M) | ($5.55M) | - | ($7.09M) | ($8.63M) | ($8.56M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.09M) | - | ($3.85M) | ($5.09M) | ($5.55M) | - | ($7.09M) | ($8.63M) | ($8.56M) | - |
| EPS - Basic | ($0.26) | - | ($0.85) | ($1.24) | ($2.10) | - | ($4.50) | ($5.70) | ($6.00) | - |
| EPS - Diluted | ($0.26) | - | ($0.85) | ($1.24) | ($2.10) | - | ($4.50) | ($5.70) | ($6.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.16M | $27.31M | $10.96M | $13.50M | $12.16M | $11.39M | $4.26M | $10.48M | $13.27M | $21.54M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $449.0K | $309.0K | $204.0K | $379.0K | $575.0K | $389.0K | $1.14M | $1.44M | - | $924.0K |
| Current Assets | $22.66M | $27.88M | $11.77M | $13.74M | $12.72M | $12.58M | $6.70M | $12.68M | - | $24.63M |
| Total Assets | $26.27M | $32.28M | $16.77M | $19.37M | $19.87M | $20.94M | $15.97M | $22.50M | - | $33.71M |
| Current Liabilities | $2.16M | $3.16M | $1.70M | $1.95M | $2.96M | $3.08M | $3.63M | $4.76M | - | $5.39M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.48M | $4.72M | $3.58M | $4.13M | $5.99M | $6.47M | $7.38M | $8.88M | - | $8.77M |
| Stockholders' Equity | $22.78M | $27.56M | $13.19M | $15.24M | $13.88M | $14.48M | $8.59M | $13.62M | $17.53M | $24.94M |
| Retained Earnings | ($146.19M) | ($141.10M) | ($136.15M) | ($132.30M) | ($127.21M) | ($121.66M) | ($115.50M) | ($108.41M) | - | ($91.22M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.95M) | - | - | - | ($3.12M) | - | - | - | ($7.92M) | - |
| Investing Cash Flow | ($9.0K) | - | - | - | $0 | - | - | - | ($71.0K) | - |
| Financing Cash Flow | ($195.0K) | - | - | - | $3.89M | - | - | - | ($277.0K) | - |
| CapEx | - | - | - | - | $0 | - | - | - | $50.0K | - |
| Free Cash Flow | - | - | - | - | ($3.12M) | - | - | - | ($7.97M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.56 | - | - | - | 0.93 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.4% | - | -23.0% | -26.3% | -27.9% | - | -44.4% | -38.4% | - | - |
| Return on equity | -22.3% | - | -29.2% | -33.4% | -40.0% | - | -82.5% | -63.4% | -48.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.50 | 8.82 | 6.91 | 7.03 | 4.30 | 4.08 | 1.84 | 2.66 | - | 4.57 |
| Quick ratio | 10.50 | 8.82 | 6.91 | 7.03 | 4.30 | 4.08 | 1.84 | 2.66 | - | 4.57 |
| Cash ratio | 10.27 | 8.64 | 6.44 | 6.91 | 4.11 | 3.69 | 1.17 | 2.20 | - | 3.99 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.15 | 1.17 | 1.27 | 1.27 | 1.43 | 1.45 | 1.86 | 1.65 | - | 1.35 |
| Liabilities / Assets | 0.13 | 0.15 | 0.21 | 0.21 | 0.30 | 0.31 | 0.46 | 0.39 | - | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.3x | - | 0.7x | 0.6x | 30.0x | - | 44.6x | 84.2x | 87.4x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 8.3% | - | 45.6% | 41.0% | 35.2% | - | 1.2% | -11.8% | -13.8% | - |
| Net income growth (YoY) | 8.3% | - | 45.6% | 41.0% | 35.2% | - | 1.2% | -11.8% | -13.8% | - |
| EPS growth (YoY) | 87.6% | - | 81.1% | 78.2% | 65.0% | - | -1856.5% | -2011.1% | -1900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 60.8% | - | - | - | -7.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 64.2% | 90.3% | 53.6% | 11.9% | -20.8% | -41.9% | -51.6% | -37.5% | 4.4% | 9.7% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing IN8BIO against the 5 most active filers in the same SIC group.